In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Diabetes Assays are tests to first diagnose diabetes and assess the risk of diabetes, such as pre-diabetes, through analysis of blood. GlobalData uses proprietary data and analytics to provide a comprehensive report on the diabetes assays devices market, including market shares of different players within China. Buy the latest report here.

Smarter leaders trust GlobalData


Premium Insights China Diabetes Assays Market Share

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

In 2022, GlobalData’s Market Model methodology determined that the leading player in the diabetes assays market in China was F. Hoffmann-La Roche followed by Siemens, Abbott Laboratories, Bio-Rad Laboratories, Tosoh, Quidelortho, Danaher, EKF Diagnostics, Sinocare and DiaSorin.

The Diabetes Assays market comprises C-Peptide Assay, Glycated Hemoglobin (HbAc) Lab Assay, Glycated Hemoglobin (HbAc) Point of care (POC) Assay, Insulin Assay, and Fasting Glucose Assay

Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the diabetes assays devices market within China was expected to be over $90m in 2022.

For the latest complete market share analysis of diabetes assays device market in China, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.